10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue
+1.12%
EPS
+31.8%
Free cash flow
−4.61%

Quarter to September 2026, against a year earlier

58.35 0.29 +0.50%
Market cap
$7.6B
P/E
0.0×
Fwd P/E
−95.9×
Dividend yield
—
F-score
6/9
Altman Z
3.99
Beneish M
−3.23
Dividend safety
n/a

10x Genomics (TXG) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, 10x Genomics (TXG) trades at a EV/FCF of 76.8×. Over the past ten years it has ranged from −1,213× (January 2020) to 132× (October 2026); the current reading is higher than 98% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 11.9× —
FY2024 −203× —
FY2023 −92.8× —
FY2022 −21.9× —
FY2021 −129× —
FY2020 −53.7× —
FY2019 −854× —
FY2018 −7.4× —
FY2017 0.0× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 122× 228.06%
Jun 2026 37.0× 102.79%
Mar 2026 18.3× 53.05%
Dec 2025 11.9× (5.14%)
27 more quarters

Against its own ten years

Low −1,213× High 132×
Ten-year median −43.1×
Current reading's percentile 98

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on TXG